FDA requires GLP-1 warnings about rare permanent vision loss

GLP-1 drugs will carry a warning about rare vision loss, but how clearly do the studies establish the risk?

The FDA is requiring GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry warnings about non-arteritic anterior ischemic optic neuropathy, or NAION. The condition damages the optic nerve when its blood supply is restricted, potentially causing abrupt, permanent vision loss. […

Published

Visual Cheatsheet Version A for FDA requires GLP-1 warnings about rare permanent vision loss. Full text follows for assistive technology.
The FDA is requiring GLP-1 medicines, including Ozempic, Wegovy, Mounjaro and Zepbound, to carry warnings about non-arteritic anterior ischemic optic neuropathy, or NAION. The condition damages the optic nerve when its blood supply is restricted, potentially causing abrupt, permanent vision loss. [4][8] The agency's studies produced mixed results, supporting a warning about a potential risk rather than a settled causal relationship. [8] Why it matters: People taking these medicines for diabetes or weight management face a new treatment consideration: an uncommon eye complication can have permanent consequences. The FDA advises clinicians to consider discontinuing a GLP-1 drug in patients who develop NAION unless treatment benefits clearly outweigh the risk—not to stop treatment in every patient. [8] Key insights: NAION occurs in roughly two to 10 people per 100,000 in the general population; that background figure is not an estimate of the extra risk from GLP-1 treatment. [8] | Across 126 trials involving more than 130,000 patients, the FDA identified 15 probable cases: 10 among GLP-1 recipients and five among placebo recipients. Those counts alone do not establish a relative risk without the treatment-group denominators. [8] | A separate FDA study found no increased risk compared with SGLT-2 diabetes drugs, but an increase compared with DPP-4 drugs; diabetes and cardiovascular conditions also overlap with NAION risk factors. [8] Cheatsheet facts: What happened: The FDA will require GLP-1 drug labels to describe a potential NAION risk, including on Ozempic, Wegovy, Mounjaro and Zepbound. [4][8] | Why: NAION restricts blood flow to the optic nerve and can cause sudden, permanent vision loss. [8] | The catch: The evidence is mixed: one FDA study found different results depending on which diabetes medicine was used as the comparison. [8] | What's next: Manufacturers must add warnings; for patients who develop NAION, the FDA asks clinicians to weigh discontinuation against treatment benefits. [8]
X copy pack
Download cheatsheet PNG